• Arch Biopartners arranged a non-brokered private placement of 1,058,823 common shares at CAD 0.85 each to raise CAD 900,000.
• Proceeds will fund U.S. site onboarding for the Phase II LSALT peptide trial targeting cardiac surgery-associated acute kidney injury.
• Funds will also support IL-32 chronic kidney disease preclinical studies, marketing and working capital.
• An officer will subscribe for 729,411 common shares in the offering.
• Closing is expected around November 12, 2026, subject to regulatory approvals and customary conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arch Biopartners Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611060720PRIMZONEFULLFEED9872040) on November 06, 2026, and is solely responsible for the information contained therein.